Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial

Eur Urol. 2021 Oct;80(4):522-523. doi: 10.1016/j.eururo.2021.06.023. Epub 2021 Jul 14.

¹ University College London Cancer Institute, London, UK. Electronic address: g.attard@ucl.ac.uk.
² Medical Research Council Clinical Trials Unit, University College London, London, UK.
³ FASTMAN Centre of Excellence, Manchester Cancer Research Centre, Manchester, UK; Department of Surgery, Christie NHS Foundation Trust, Manchester, UK; Department of Urology, Salford NHS Foundation Trust, Manchester, UK.
⁴ Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.

No abstract available

Keywords: Abiraterone acetate; Androgen deprivation therapy; High-risk localised; Prostate cancer.

Publication types